References
- Stahl SM, Grady MM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. Cambridge (UK): Cambridge University Press; 2013.
- Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28–40.
- Hay SI, Abajobir AA, Abate KH, et al. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211–1259.
- Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021 Jun;39(6):653–665.
- Ormel J, Kessler RC, Schoevers R. Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better? Curr Opin Psychiatry. 2019 Jul;32(4):348–354.
- Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017 May;4(5):409–418.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357–1366.
- Ioannidis JP. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med. 2008 May 27;3:14.
- FDA Drug Safety Communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses [Internet]. Washington (DC): 2012 Mar 28. [cited 2021 Sept 27] Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related
- Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol. 2013 Apr;69(4):755–760.
- Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl). 2004 Jul;174(2):163–176.
- Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002 Feb;3(1):13–37.
- Stahl SM, Grady MM. Stahl’s essential psychopharmacology: prescribers guide. 6th ed. Cambridge (UK): Cambridge University Press; 2018.
- Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141–150.
- Gartlehner G, Hansen RA, Reichenpfader U, et al. Drug Class Review: second-Generation Antidepressants: final Update 5 Report [Internet]. Portland (OR): Oregon Health & Science University; 2011. Available from: https://www.ncbi.nlm.nih.gov/books/NBK54355/
- Montejo AL, Prieto N, de Alarcón R, et al. Management Strategies for Antidepressant-Related Sexual Dysfunction: a Clinical Approach. J Clin Med. 2019 Oct 7;8(10):1640.
- Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988 Jul;49(7):262–266.
- Tripp AC. Bupropion, a brief history of seizure risk. Gen Hosp Psychiatry. 2010 Mar;32(2):216–217.
- Sahli ZT, Banerjee P, Tarazi FI. The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov. 2016;11(5):515–523.
- McIntyre RS, Harrison J, Loft H, et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016 Jun 15;19(10):055.
- Tran BX, Ha GH, Vu GT, et al. Indices of change, expectations, and popularity of biological treatments for major depressive disorder between 1988 and 2017: a scientometric analysis. Int J Environ Res Public Health. 2019 Jun 26;16(13):2255.
- Hansen KB, Yi F, Perszyk RE, et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150(8):1081–1105.
- Fogaça MV, Fukumoto K, Franklin T, et al. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019 Dec;44(13):2230–2238.
- McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021 May 1;178(5):383–399.
- Perception neuroscience’s PCN-101 (R-Ketamine) demonstrates tolerability in phase 1 single ascending dose study [Internet]. New York (NY): atai Life Sciences. 2021 Feb [cited 2021 Apr]. Available from: https://www.prnewswire.com/news-releases/perception-neurosciences-pcn-101-r-ketamine-demonstrates-tolerability-in-phase-1-single-ascending-dose-study-301231491.html
- Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol. 2017 May;152:21–37.
- Fava M, Stahl S, Pani L, et al. REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a Phase 2a randomized double-blind trial. Am J Psychiatry. 2021;178(1):11.
- Higgins GA, Ballard TM, Kew JN, et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology. 2004 Jun;46(7):907–917.
- De Martin S, Gabbia D, Folli F, et al. REL-1017 (Esmethadone) increases circulating bdnf levels in healthy subjects of a phase 1 clinical study. Front Pharmacol. 2021 Apr 28;12:671859.
- Modgil A, Parakala ML, Ackley MA, et al. Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism. Neuropharmacology. 2017 Feb;113(Pt A):314–322.
- Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001 Mar 1;49(5):391–404.
- Safety A. Efficacy and biomarker study of JNJ-42847922 in participants with major depressive disorder [Internet]. Bethesda (MD): National Library of Medicine. 2017 [cited 2021 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02476058
- Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021 Apr 15;384(15):1402–1411.
- Psilocybin vs escitalopram for major depressive disorder: comparative mechanisms (Psilodep-RCT) [Internet]. Bethesda (MD): National Library of Medicine. 2020 July [cited 2021 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03429075
- Efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) [Internet]. Bethesda (MD): National Library of Medicine. 2019 Aug [cited 2021 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01715805
- Earley WR, Guo H, Németh G, et al. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull. 2018;48(4):62–80.
- Intra-Cellular therapies announces U.S. FDA approval of CAPLYTA® (lumateperone) for the treatment of bipolar depression in adults [Internet]. New York (NY): Intra-Cellular Therapies; 20 Dec. [cited 20 Dec 24]. Available from: https://ir.intracellulartherapies.com/node/12151/pdf
- Kumar B, Kuhad A, Kuhad A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today (Barc). 2018 Dec;54(12):713–719.
- Clinical trial of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder [Internet]. Bethesda (MD): National Library of Medicine. 2019 Aug [cited 2021 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04985942
- Hecking J, Davoudian PA, Wilkinson ST. Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders. chronic stress (Thousand Oaks). Chronic Stress (Thousand Oaks, Calif.). 2021 Jun 2;5:24705470211020446.
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results [Internet]. Boston MA): Praxis Medicines. 2021 May 11 [cited 2021 Dec 20]. Available from: https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-0
- A clinical trial of prax-114 in participants with major depressive disorder [Internet]. Bethesda (MD): National Library of Medicine. 2021 Dec [cited 2021 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04832425
- A study to evaluate the efficacy of sage-217 in the treatment of adult participants with Major Depressive Disorder (MDD) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Jan [cited 2021 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04442490
- Sage therapeutics and biogen announce positive pivotal phase 3 results for zuranolone, an investigational two-week, once-daily therapeutic being evaluated for major depressive disorder [Internet]. Boston (MA): Biogen. 2021 Jun 15 [cited 2021 Dec 20]. Available from: https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3
- Pothula S, Liu RJ, Wu M, et al. Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. Neuropsychopharmacology. 2021 Mar;46(4):799–808.
- AGN-241751 in the treatment of major depressive disorder [Internet]. Bethesda (MD): National Library of Medicine. 2019 Oct [cited 2021 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03726658
- Assessing Symptomatic Clinical Episodes in Depression (ASCEND) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Sept [cited 2021 Dec 22. Available from: https://clinicaltrials.gov/ct2/show/NCT03595579
- A trial of axs-05 in patients with major depressive disorder (GEMINI) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Sept [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04019704
- Mechanistic Evaluation of Response in TRD (MERIT) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Jul [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04608396
- A study of CLE-100 (Oral Esketamine) in addition to standard antidepressant drug for major depressive disorder - CLEO study [Internet]. Bethesda (MD): National Library of Medicine. 2021 Dec [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04103892
- Bernstein G, Davis K, Mills C, et al. Characterization of the safety and pharmacokinetic profile of D-Methadone, a Novel N-Methyl-D-Aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 Studies. J Clin Psychopharmacol. 2019 May;39(3):226–237.
- A study to assess the efficacy and safety of rel-1017 as adjunctive treatment for Major Depressive Disorder (MDD) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Sept [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT05081167
- A study to assess the efficacy and safety of rel-1017 as monotherapy for Major Depressive Disorder (MDD) (RELIANCE-III) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Sept [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04855747
- Relmada announces FDA FAST TRACK DESIGNATION FOR D-METHADONE FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER [Internet]. Coral Gables (FL): relmada therapeutics, Inc. 2017 April [cited 2021 Dec 22]. Available from: https://www.relmada.com/investors/news/press-releases/detail/175/relmada-announces-fda-fast-track-designation-for
- Efficacy and safety of MK-1942 when added to stable antidepressant therapy in participants with Treatment-Resistant Depression (TRD) (MK-1942-006) Disorder [Internet]. Bethesda (MD): National Library of Medicine. 2021 Dec [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04663321
- Study in major depressive disorder with BTRX-335140 vs Placebo [Internet]. Bethesda (MD): National Library of Medicine. 2021 Oct [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04221230
- Krystal AD, Pizzagalli DA, Smoski M, et al. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 May;26(5):760–768.
- Savitz A, Wajs E, Zhang Y, et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int J Neuropsychopharmacol. 2021 Dec 8;24(12):965–976.
- Recourt K, de Boer P, Zuiker R, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry. 2019 Sep 3;9(1):216.
- A study of seltorexant as adjunctive therapy to antidepressants in adult and elderly participants with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant and long-term safety extension treatment with seltorexant [Internet]. Bethesda (MD): National Library of Medicine. 2022 Jan [cited 2021 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04533529
- Gill H, Gill B, Chen-Li D, et al. The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Rev Neurother. 2020Dec;20(12):1263–1273. Epub 2020 Sep 30. PMID: 32954860.
- Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017 Feb;101(2):209–219.
- Psilocybin and depression (Psilo101) disorder [Internet]. Bethesda (MD): National Library of Medicine. 2017 Dec [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03380442
- A study of psilocybin for Major Depressive Disorder (MDD) disorder [Internet]. Bethesda (MD): National Library of Medicine. 2021 Dec [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03866174
- Psilocybin for treatment-resistant depression disorder [Internet]. Bethesda (MD): National Library of Medicine. 2021 Dec [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT05029466
- Psilocybin - induced neuroplasticity in the treatment of major depressive disorder [Internet]. Bethesda (MD): National Library of Medicine. 2021 Nov [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03554174
- Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) [Internet]. Bethesda (MD): National Library of Medicine. 2021 July [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04670081
- Psilocybin in Depression Resistant to Standard Treatments (PsiDeR) [Internet]. Bethesda (MD): National Library of Medicine. 2021 July [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04959253
- The safety and efficacy of psilocybin in participants with treatment resistant depression (P-TRD) [Internet]. Bethesda (MD): National Library of Medicine. 2021 June [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03775200
- Assessing the efficacy of micro-dosed psilocybin on reducing anxiety & depression levels in adults [Internet]. Bethesda (MD): National Library of Medicine. 2021 Aug [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04989972
- Clinical, neurocognitive, and emotional effects of psilocybin in depressed patients - proof of concept [Internet]. Bethesda (MD): National Library of Medicine. 2021 Sep [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03715127
- PSIL201 long-term follow-up study: psilocybin or niacin/major depressive disorder [Internet]. Bethesda (MD): National Library of Medicine. 2021 Sep [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04353921
- Psilocybin treatment of major depressive disorder with co-occurring alcohol use disorder (PsiloMDDAUD) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Apr [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04620759
- The effect of psilocybin on mdd symptom severity and synaptic density (PSIPET) [Internet]. Bethesda (MD): National Library of Medicine. 2021 Nov [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04630964
- Frontline clinician psilocybin study [Internet]. Bethesda (MD): National Library of Medicine. 2022 Jan [cited 2021 Dec 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT05163496
- Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul;3(7):619–627.
- Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018 Feb;235(2):399–408.
- Arrivo bioventures emerges from stealth mode with a robust pipeline and promising data [Internet]. Morrisville (NC): Arrivo BioVentures. 2021 Dec [cited 2021 Dec 23]. Available from: https://arrivobio.com/content/uploads/2021/12/Arrivo-Emerges-Press-Release-Final-with-logo.pdf